ACET ADICET BIO INC Expansion Plans 8-K Filing 2024 - Strategic Focus Shift Adicet Bio, Inc. is shifting its focus to develop ADI-001 for autoimmune diseases, closing patient enrollment for its lymphoma study, which showed an 80% overall response rate in treated patients.Get access to all SEC 8-K filings of the ADICET BIO INC